news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

on september 18, hainan haiyao (sz000566) hit the limit down. as of the close, it was reported at 4.89 yuan. there were over one million orders placed on the limit down board, and the transaction volume exceeded 200 million yuan.prior to this, the stock had hit the daily limit for six consecutive trading days.

on the evening of september 17, hainan haiyao announced that the company's stock price has risen sharply in the short term recently, which is obviously deviated from the market trend, and there is a risk of overheated market sentiment. however, there are no major changes in the company's fundamentals, and there is no major information that should be disclosed but has not been disclosed. in the first half of 2024, the company is in a loss-making state.

hainan haiyao said that its shareholding company hainan unicore biotechnology co., ltd. is mainly engaged in human somatic cell preparation, storage, application technology research and drug development. its main business is cell preparation and storage. unicore has been in the stage of r&d investment and market development.it has not yet made a profit.

as of december 31, 2023, the company has made an asset impairment provision of rmb 1,714,944.81 for unicol's long-term equity investment, and the book value of unicol is rmb 0 as of december 31, 2023. there are uncertainties in the future technology research and development, competitiveness, etc. of related products, and the industry is affected by various factors such as future changes in market demand, industry and national policies, and there are also uncertainties.

except for hainan haiyao, there was a clear differentiation in the concept of state-owned enterprise reform in the morning: huaying technology hit the limit, jinguan shares fell more than 9%; ruitai technology, longgao shares, haili shares, changshan beiming and many other stocks hit the limit.